What is the recommended fourth-line treatment for a patient with relapsed follicular lymphoma after three prior regimens, considering EZH2 mutation status?

Fourth-Line Treatment for Relapsed Follicular Lymphoma

For patients with relapsed follicular lymphoma after three prior regimens, prioritize CD19-directed CAR T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel) or CD3×CD20 bispecific antibodies (mosunetuzumab or epcoritamab) as fourth-line options, with EZH2 mutation testing reserved for patients who are not candidates for these cellular or bispecific therapies. 1

Treatment Algorithm Based on Patient Characteristics

First-Tier Options (Approved for ≥2 Prior Lines)

CAR T-Cell Therapies:

• Axicabtagene ciloleucel, tisagenlecleucel, or lisocabtagene maraleucel are approved after ≥2 prior systemic therapies 1
• These demonstrate the highest 24-month PFS rates (62-65%) and RMST24 values (18.6-19.5 months) among available options 2
• Consider for younger patients with adequate organ function and performance status who can tolerate lymphodepleting chemotherapy
• Particularly appropriate for patients with early relapse (<24 months from initial diagnosis), which indicates poor prognosis 1

CD3×CD20 Bispecific Antibodies:

• Mosunetuzumab or epcoritamab are approved after ≥2 prior therapies 1
• 24-month PFS rates of 43-49% with more manageable outpatient administration 2
• Preferred for patients who cannot undergo CAR T-cell therapy due to comorbidities, age, or logistical constraints
• Require cytokine release syndrome (CRS) monitoring, particularly during step-up dosing 3

Second-Tier Options

BTK Inhibitor Combination:

• Zanubrutinib + obinutuzumab shows 24-month PFS of 53.8% 2
• Consider for patients preferring oral therapy or those with contraindications to cellular therapies
• Requires extended anti-CD20 exposure

Tafasitamab + Lenalidomide + Rituximab:

• The inMIND trial demonstrated improved PFS when tafasitamab was added to lenalidomide-rituximab 1
• Appropriate for patients who previously responded to lenalidomide-based therapy (>6-12 months duration) 4

EZH2 Mutation-Directed Therapy

Tazemetostat:

• FDA-approved for EZH2-mutated FL after ≥2 prior lines, or EZH2 wild-type without alternative options 5
• EZH2 mutations occur in ~17-20% of FL cases 6, 7
• Reserve testing for patients who are not candidates for CAR T-cell therapy or bispecific antibodies, as these cellular/immunotherapies show superior durability outcomes
• EZH2-mutated FL demonstrates distinctive features: clearer neoplastic follicles, greater interfollicular spread, and typical CD10+/BCL2+/BCL6+ immunophenotype 6
• Mutation status remains concordant in 94% of cases between primary and relapsed disease 6

Critical Decision Points

When to Choose CAR T-Cell Therapy:

• Age <70 with good performance status
• Early relapse (<24 months from diagnosis)
• Adequate organ function for lymphodepletion
• Access to certified treatment center
• Patient preference for potentially curative approach despite higher upfront toxicity risk

When to Choose Bispecific Antibodies:

• Older patients or significant comorbidities
• Inability to travel to CAR T center
• Need for outpatient management
• Concern about prolonged cytopenias from CAR T
• Patient preference for incremental dosing approach

When to Test EZH2 Status:

• Patient declines or is ineligible for CAR T or bispecific therapy
• Significant comorbidities precluding intensive immunotherapy
• Need for oral therapy option
• Limited treatment options exhausted

Common Pitfalls to Avoid

1. Don't reflexively test EZH2 in all patients - The 2025 NCCN guidelines prioritize CAR T and bispecific antibodies over mutation-directed therapy 1

2. Don't overlook early relapse timing - POD <24 months from diagnosis warrants aggressive therapy consideration, favoring CAR T approaches 1

3. Don't forget CRS prophylaxis - Bispecific antibodies require 3-step step-up dosing with hydration and dexamethasone to minimize CRS 3

4. Don't ignore prior rituximab exposure - Duration of response to prior anti-CD20 therapy informs subsequent treatment selection 4

5. Don't assume all fourth-line options are equivalent - Reconstructed data shows CAR T therapies have numerically superior 24-month PFS (62-65%) compared to bispecifics (44-49%) or other options, though confidence intervals overlap 2

Nuances in Evidence

The 2025 NCCN guidelines 1 represent the most current framework and clearly establish CAR T and bispecific antibodies as preferred options after ≥2 prior lines. The older 2021 ESMO guidelines 4 predate these approvals and focus on lenalidomide-rituximab and PI3K inhibitors, which are now superseded by newer cellular therapies.

The key paradigm shift is that EZH2 mutation status is no longer a first-line consideration in treatment selection for fourth-line therapy - it becomes relevant only when cellular and bispecific immunotherapies are not feasible. This reflects the superior durability outcomes demonstrated with CAR T and bispecific approaches in recent comparative analyses 2.

For patients with short remissions after prior chemoimmunotherapy, the evidence supports moving directly to novel mechanisms (CAR T, bispecifics) rather than re-challenging with different chemotherapy combinations 4.